Proton Pump Inhibitors and Biomarkers of Haemostasis in Postmenopausal Women: The Buffalo OsteoPerio Study
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Ahmed I Soliman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Environmental Health, University at Buffalo - SUNY, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Hemostasis, Proton Pump Inhibitors, Postmenopause. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, U.S. Army Reserve Medical Corps, National Institute for Dental and Craniofacial Research.
Abstract (Originalsprache)
Aims
Examine the association between proton pump inhibitor (PPI) use and plasma levels of four biomarkers of haemostasis: fibrinogen, von Willebrand factor (vWF), high‐sensitivity CRP (hs‐CRP) and plasminogen activator inhibitor‐1 (PAI‐1) in postmenopausal women.
Methods
We conducted a cross‐sectional analysis on 200 women in the Buffalo Osteoporosis and Periodontitis study Year 17 visit. PPI use was assessed using medication inventories, and biomarkers were measured using frozen plasma samples. Linear regression was used to estimate mean differences for each biomarker according to PPI use (yes/no) and duration (≤ 1 year, > 1 year). Logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for having a high versus low level of each biomarker. Models were adjusted for major cardiovascular risk factors to account for potential confounding.
Results
PPI users had non‐statistically significant higher levels of vWF (mean difference = 52.9 mIU/mL, p = 0.38) and log hs‐CRP (mean difference = 0.1 mg/L, p = 0.5) compared to non‐users. PPI users for > 1 year had non‐statistically significant higher odds of having a high level of vWF (OR = 1.08, 95% CI: 0.51–2.31) and hs‐CRP (OR = 1.16, 95% CI: 0.58–2.33) compared to non‐users.
Conclusions
There was no significant association between PPI use and measured plasma haemostatic markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Environmental Health, University at Buffalo - SUNY, Buffalo, New York, USA.
ORCID-Profile: Ahmed I Soliman
Förderung
- NIDCR NIH HHS
- U.S. Army Reserve Medical Corps
- National Institute for Dental and Craniofacial Research
- Saxon Graham Research Award
- American Heart Association-American Stroke Association
- Mark Diamond Research Fund
- American Heart Association
Zitieren
APA
Soliman, A. I., Wactawski-Wende, J., Millen, A. E., Hovey, K. M., & LaMonte, M. J. (2026). Proton Pump Inhibitors and Biomarkers of Haemostasis in Postmenopausal Women: The Buffalo OsteoPerio Study. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70156
Vancouver
Soliman AI, Wactawski-Wende J, Millen AE, Hovey KM, LaMonte MJ. Proton Pump Inhibitors and Biomarkers of Haemostasis in Postmenopausal Women: The Buffalo OsteoPerio Study. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70156
BibTeX
@article{Soliman2026,
author = {Soliman, Ahmed I and Wactawski-Wende, Jean and Millen, Amy E and Hovey, Kathleen M and LaMonte, Michael J},
title = {Proton Pump Inhibitors and Biomarkers of Haemostasis in Postmenopausal Women: The Buffalo OsteoPerio Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70156}
}
EUVIMED